WASHINGTON--(BUSINESS WIRE)--Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivate’s June 30, 2021, Journal Citation Report for 2020.
The highly anticipated 2020 impact factor is one journal quality and importance measure. The impact factor calculates how often articles published in the journal in 2018 and 2019 were cited in other published research articles in 2020.
“We are very pleased with our first impact factor,” said Mark Dransfield, MD, Editor in Chief of the JCOPDF. “Our journal is only seven years old, launched in 2014 by founding Editor in Chief James D. Crapo, MD, and the COPD Foundation’s founder, the late John W. Walsh. They envisioned an open access journal that could become the publishing home for important COPD-related research. And now their vision has been validated with this impact factor which categorizes the JCOPDF as the highest-ranked COPD-focused journal.”
Devoted to publishing original research, reviews, and perspectives on COPD—the fourth leading cause of death in the United States and the third leading cause of death worldwide—the JCOPDF has an editorial board of global COPD experts from 15 countries. It is published online quarterly with no barriers to access.
“For a non-profit foundation to publish a medical journal is no small feat, particularly in these times of large, multi-faceted, competing publishing conglomerates,” said Ruth Tal-Singer, PhD, President and Chief Scientific Officer of the COPD Foundation. “But encouraging and fostering innovative research and education is a critical part of the COPD Foundation’s mission. To receive this ranking—with our first impact factor—is both encouraging and reaffirming of our goals to understand COPD, bronchiectasis, and nontuberculous mycobacterial lung disease better, improve the lives of those who live with these devastating conditions, and ultimately find a cure.”
The COPD Foundation is a not-for-profit organization that was established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations which will make treatment more effective and affordable. We do this through scientific research, education, advocacy, and awareness with the goal of disease prevention, slowed progression, and ultimately a cure. Visit www.copdfoundation.org
